Leonteq Securities AG Decreases Position in DaVita Inc. $DVA

Leonteq Securities AG lowered its stake in DaVita Inc. (NYSE:DVA) by 87.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 346 shares of the company’s stock after selling 2,482 shares during the quarter. Leonteq Securities AG’s holdings in DaVita were worth $53,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares in the last quarter. Norges Bank acquired a new position in DaVita in the 4th quarter worth $49,164,000. Corient Private Wealth LLC boosted its position in DaVita by 1,493.1% in the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares during the last quarter. Man Group plc grew its stake in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its position in shares of DaVita by 2,905.7% during the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after acquiring an additional 220,628 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 1.5%

NYSE:DVA opened at $230.75 on Thursday. The stock has a 50 day moving average of $201.31 and a 200-day moving average of $159.01. The firm has a market capitalization of $14.81 billion, a PE ratio of 21.41, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $239.64.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the topic of several recent analyst reports. UBS Group boosted their price target on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Barclays set a $218.00 price objective on DaVita in a report on Wednesday. Truist Financial upped their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. TD Cowen lifted their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $203.17.

Insider Buying and Selling at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.50% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.